Oncopeptides Balance Sheet Health

Financial Health criteria checks 5/6

Oncopeptides has a total shareholder equity of SEK56.8M and total debt of SEK106.5M, which brings its debt-to-equity ratio to 187.5%. Its total assets and total liabilities are SEK238.4M and SEK181.6M respectively.

Key information

187.5%

Debt to equity ratio

SEK 106.49m

Debt

Interest coverage ratio	n/a
Cash	SEK 173.44m
Equity	SEK 56.78m
Total liabilities	SEK 181.60m
Total assets	SEK 238.38m

Recent financial health updates

No updates

Recent updates

Financial Position Analysis

Short Term Liabilities: ONCO BTA's short term assets (SEK202.9M) exceed its short term liabilities (SEK44.9M).

Long Term Liabilities: ONCO BTA's short term assets (SEK202.9M) exceed its long term liabilities (SEK136.7M).

Debt to Equity History and Analysis

Debt Level: ONCO BTA has more cash than its total debt.

Reducing Debt: ONCO BTA's debt to equity ratio has increased from 0% to 187.5% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ONCO BTA has sufficient cash runway for 7 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: ONCO BTA is forecast to have sufficient cash runway for 9 months based on free cash flow estimates, but has since raised additional capital.

Discover healthy companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/05/15 23:58
End of Day Share Price	2024/05/13 00:00
Earnings	2023/12/31
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Oncopeptides AB (publ) is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Erik Hultgård	Carnegie Investment Bank AB
Patrik Ling	DNB Markets
Robert Burns	H.C. Wainwright & Co.